Give me full A2 style detailed answer with all introduction all etiology all pathology all pathophysiology all classification all pathogenesis all clinical features all diagnosis all treatment all hrct findings and drug with doses newer therapy from fishman and ers guidelines of non resolving pneumonia
Checking Date & Time
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Searching PubMed
"non-resolving pneumonia" OR "nonresolving pneumonia"
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Searching PubMed
"community acquired pneumonia" AND "treatment failure" AND management
Reading File
Finding Sources
This is your full A2-style detailed answer on Non-Resolving Pneumonia, synthesized primarily from Fishman's Pulmonary Diseases and Disorders and Murray & Nadel's Textbook of Respiratory Medicine, cross-referenced with ERS guidelines and current PubMed evidence. Here is a structured summary of what was covered:
What Was Covered
1. Introduction & Definition
Defined as no clinical improvement after ≥10 days of antibiotics or failure of radiographic clearing by 2–3 months. Two patterns: progressive/deteriorating (septic shock trajectory) vs. nonresponding (persistent fever/symptoms without deterioration). Evaluate formally at 72 hours.
2. Etiology
Three major categories:
- Infectious (~40%): Resistant organisms (DRSP, MRSA, MDR P. aeruginosa), unusual pathogens (TB, NTM, fungi, PJP, Nocardia), and infectious complications (empyema, abscess, metastatic infection)
- Noninfectious (~22%): COP/BOOP, eosinophilic pneumonia, organizing diseases, vasculitis (GPA, MPA), pulmonary infarction, drug-induced, malignancy (lepidic adenocarcinoma is a classic mimic)
- Unknown (~30%): No specific cause despite full workup
3. Pathophysiology & Pathogenesis
Covers microbiological failure, host defense dysfunction (neutrophil/B-cell/T-cell/structural defects), anatomical obstruction, inflammatory dysregulation, and organism-specific virulence mechanisms.
4. Classification
By time course (slow-resolving, nonresponding, progressive, recurrent), by etiology (infectious/noninfectious/unknown), by host status, and the Kuru & Lynch 3-type classification.
5. Clinical Features
Persistent fever, hemoptysis, extrapulmonary clues (joint pain → vasculitis; night sweats → TB; renal impairment → Goodpasture/GPA). Biomarker red flags: persistently elevated PCT/CRP/IL-6.
6. Diagnosis
A stepwise approach: 72-hour reassessment → intensified microbiology (cultures, serology, galactomannan, ANCA/ANA, HIV) → HRCT → bronchoscopy with BAL/biopsy → surgical lung biopsy/EBUS for selected cases. Thoracentesis is mandatory for any pleural effusion.
7. HRCT Findings (Extensive)
Detailed pattern-recognition table covering:
- Infectious: tree-in-bud (TB/NTM), halo sign (aspergillosis), cavitation (abscess/TB), necrotizing pneumonia, miliary
- Noninfectious mimics: reverse halo/atoll sign (COP), peripheral upper-lobe consolidation (CEP), perilymphatic nodules (sarcoidosis), CT angiogram sign (BAC/lepidic adenocarcinoma), Hampton's hump (PE)
8. Treatment
Full antibiotic protocol including:
- Empirical broadening strategies (add MRSA + Pseudomonas coverage)
- Organism-directed therapy with drugs and doses for all major pathogens
- Newer antibiotics: Ceftazidime-avibactam, Ceftolozane-tazobactam, Cefiderocol, Meropenem-vaborbactam, Imipenem-relebactam, Omadacycline, Lefamulin, Isavuconazole, Baloxavir
- Noninfectious treatment: steroids for COP/eosinophilic pneumonia/HP/drug-induced, immunosuppressants for vasculitis, intrapleural tPA+DNase for empyema
- Adjunctive dexamethasone for severe ICU CAP (per ERS 2021 + Chest 2023 meta-analysis)
9. ERS Guidelines
10 key ERS recommendations including CT/bronchoscopy indications, PCT monitoring, antibiotic stewardship, drainage protocols, and steroid use.
This is a shared conversation. Sign in to Orris to start your own chat.